Photo via The Sydney Morning Herald

She lost 10kg of muscle and gained fat: The hidden risk of weight-loss drugs

Read the original at The Sydney Morning Herald ↗
Cite

Aubusson, K. (2026, November 22). She lost 10kg of muscle and gained fat: The hidden risk of weight-loss drugs. The Sydney Morning Herald. https://www.smh.com.au/healthcare/she-lost-10kg-of-muscle-and-gained-fat-the-hidden-risk-of-weight-loss-drugs-20261122-p61g17.html?ref=rss&utm_medium=rss&utm_source=rss_feed

Dated from the outlet's own feed. Check the original for its byline.

The Sydney Morning Herald · collected 2026-11-22 · by Kate Aubusson

Quick Summary

Dr. Kean-Seng Lim, a GP in Mount Druitt, warns of the risks associated with GLP-1 medications like Wegovy and Ozempic, which are used to manage chronic weight. One of his patients, a woman over 60, experienced a significant loss of muscle mass and gained fat while taking GLP-1 medications without proper monitoring or dietary guidance. She lost 10 kilograms of muscle and gained 1 kilogram of fat, increasing her risk of falls. The article highlights the importance of proper monitoring and lifestyle changes to mitigate the potential adverse effects of these drugs.
Written by AI on 2026-11-22, from this article's own text only (the story summary below draws on all the coverage).

AI analysis

Story summary

A woman in western Sydney, prescribed GLP-1 weight-loss drugs like Wegovy, lost 10 kilograms of muscle mass and gained fat due to inadequate follow-up and dietary advice. Dr. Kean-Seng Lim, a GP and former president of the Australian Medical Association NSW, warns that while GLP-1 drugs can be effective when used correctly, they pose significant risks if not managed properly. The surge in demand for these medications is expected to increase with the arrival of oral GLP-1 drugs like Novo Nordisk’s Wegovy and Lilly’s Foundayo. These drugs, when combined with diet and exercise, can lead to significant weight loss and reduce the risk of heart attack, stroke, and cardiovascular death. However, without proper guidance, patients may experience muscle wastage and weight rebound.

Written for “Weight Loss Drug Risks” on 2026-11-22, grounded in this article and the 0 other(s) covering the same event.

Compared with similar articles

Nothing to compare against. No article is close enough to this one for the pipeline to have linked or judged the pair.

Story

Weight Loss Drug Risks
Health · 1 article(s) covering the same event.
How this article was measured signals, leaning charts, publisher record, byline, topics and claims

Signals How these are calculated →

Claims extracted
17
sentences that state something as happening or true
Uncertain
6%
1 of 17 hedged ("reportedly", "may", "according to")
Leaning
not political
takes no side on a contested political question
Publisher signals
61/100
The Sydney Morning Herald's corrections and hedging, across everything collected from it. Not a measure of accuracy.
Outlets on this story
1
Health
Same framing elsewhere
1
articles that frame the event the way this one does
Analyzed 2026-11-22 · how these are computed

How this is being covered How these are calculated →

Article leaning vs. publisher reliability
Source leaning vs. consistency

Publisher

The Sydney Morning Herald · 7886 article(s) · 16 correction(s) detected
Running correction rate · 16 correction(s)

Who wrote this

Kate Aubusson
6 article(s) here · 1 carrying a prediction
A surge in demand for GLP-1 medications is expected to accelerate, with the first two oral GLP-1s – Novo Nordisk’s Wegovy pill and Lilly’s Foundayo – arriving at pharmacies for patients with private prescriptions.
The first analysis of the trial suggests thousands more men with prostate cancer could benefit from the medication.
Emergency departments will brace for a 411 per cent increase in patients aged 85 and over by 2050, the latest Australasian College of Emergency Medicine’s State of Emergency 2026 report revealed.
Under Section 19b of the Mental Health and Cognitive Impairment Forensic Provisions Act, magistrates can send people who may be mentally ill or impaired to public hospitals where they are detained and undergo psychiatric assessment.
She could not record Joe’s heart rate, but recorded an abnormally fast respiratory rate of 57.
Also by Kate Aubusson
Nothing else under this byline is closely related to this article, so these are simply their most recent.
All 6 articles by Kate Aubusson →

Topics

Australian Medical Association NSW Lilly Novo Nordisk’s Sydney Wegovy

Subjects

Lim PERSON · 3× Kean-Seng PERSON · 2× Australian NORP · 1× Australian Medical Association NSW ORG · 1× EY-Parthenon ORG · 1× Kean-Seng Lim PERSON · 1× Lilly ORG · 1× Novo Nordisk’s ORG · 1× Sydney GPE · 1×

Narrative

She had been prescribed GLP-1s via another provider with no follow-up or diet and exercise advice, reduced her food intake and, critically, wasn’t eating enough protein, Kean-Seng said. “On further assessment using a body composition analysis, we found that she had lost 10 kilograms of muscle mass and gained one kilogram of fat mass, and she was now at quite a significant risk of falls,” Lim said.
framing: assertive · carried by 1 article(s) · first seen 2026-11-22
A surge in demand for GLP-1 medications is expected to accelerate, with the first two oral GLP-1s – Novo Nordisk’s Wegovy pill and Lilly’s Foundayo – arriving at pharmacies for patients with private prescriptions.
2026-11-22 · The Sydney Morning Herald
She lost 10kg of muscle and gained fat: The hidden risk of weight-loss drugs · assertive framing

Claims (17 extracted, 1 hedged)

At a Mount Druitt medical practice where four in five patients are overweight and obese, a woman struggles to rise from her chair, her muscles having wasted away. asserted
muscles → struggle → chair
“They are powerful tools if used well, but they can be a double-edged sword,” Lim, a GP for more than 30 years and former Australian Medical Association NSW president. asserted
they → use → years
A surge in demand for GLP-1 medications is expected to accelerate, with the first two oral GLP-1s – Novo Nordisk’s Wegovy pill and Lilly’s Foundayo – arriving at pharmacies for patients with private prescriptions. asserted
GLP-1s → expect → prescriptions
GLP-1s, approved for chronic weight management when combined with diet and exercise, can be life-changing, triggering significant weight loss and lowering the risk of obesity-related health complications. asserted
GLP-1s → approve → complications
Semaglutides have also been shown to lower the risk of heart attack, stroke and cardiovascular death. asserted
Semaglutides → show → attack
But clinicians and researchers have cautioned against mistaking GLP-1s for a silver bullet, warning muscle wastage and a great weight rebound was on the horizon for those who do. “But worryingly, the focus for these agents has been on weight, rather than health,” Lim said. asserted
Lim → caution → health
Kean-Seng recalled one of his patients, a woman aged over 60, who was having great difficulty getting out of her chair. asserted
who → recall → chair
She had been prescribed GLP-1s via another provider with no follow-up or diet and exercise advice, reduced her food intake and, critically, wasn’t eating enough protein, Kean-Seng said. “On further assessment using a body composition analysis, we found that she had lost 10 kilograms of muscle mass and gained one kilogram of fat mass, and she was now at quite a significant risk of falls,” Lim said. asserted
Lim → prescribe → falls
“As with any powerful drug, we have got to use it properly. asserted
we → get → it
We need to be monitoring patients properly, ideally through a multidisciplinary team, because there are very real risks.” asserted
We → need → team
Among them was malnutrition, muscle wastage and developing unhealthy eating habits “such that they either rapidly regain weight when they stop [using GLP-1s] or they end up worse off with lower muscle mass, increased risk of falls and increased risk of other harms. asserted
they → develop → harms
By 2036, between 17 and 30 per cent of the Australian population – up to 7 million people – could be using GLP-1s, according to EY-Parthenon modelling published in July. uncertain
cent → use → July
Clinical trials and real-world data consistently shows that stopping GLP-1 use leads to a rapid rebound in weight and a reversal of improvements in cardio-metabolic risk factors. asserted
stopping → show → factors
“Ultimately, we do find that very few patients actually stay on these medications on an ongoing basis even though all the studies have shown that once the medication stops, there is usually great weight gain,” Lim said. asserted
Lim → find → basis
He said responsible GLP-1 use involves planning for this eventuality by adopting healthy diet and exercise habits so that they don’t regain the weight they lost, or keep the regained weight to a minimum. asserted
they → say → minimum
“On the bright side, when used well and with good nutritional support, preferably with an experienced dietitian, and with good exercise support, we can get very good results,” he said. asserted
he → use → results
“In the best-case scenario, we have patients who either maintain or even improve their muscle mass while reducing fat mass, which we know improves their metabolic rate and reduced their rate of weight regain.” asserted
we → have → regain
Give feedback · no sign-in needed

No sign-in needed for now. Your note is sent without a name, so it cannot be answered.

History Support